PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. [electronic resource]
Producer: 20191024Description: 531-538 p. digitalISSN:- 1095-6859
- Adult
- Aged
- Anastrozole -- adverse effects
- Antineoplastic Agents, Hormonal -- adverse effects
- Carcinoma, Ovarian Epithelial -- drug therapy
- Cystadenocarcinoma, Serous -- drug therapy
- Female
- Humans
- Middle Aged
- Neoplasm Grading
- Neoplasm Recurrence, Local -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Postmenopause
- Progression-Free Survival
- Prospective Studies
- Quality of Life
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.